Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

about

Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.

P2860

Q39698913-067E4D84-86BB-44E1-B96B-06188404F718

P2860

Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Item

http://www.wikidata.org/entity/Q38894275

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Controlling chemotherapy-induc ...... factors among Korean patients.

@en

type

Item

label

Controlling chemotherapy-induc ...... factors among Korean patients.

@en

prefLabel

Controlling chemotherapy-induc ...... factors among Korean patients.

@en

P1476

Controlling chemotherapy-induc ...... factors among Korean patients

@en

P2093

Chung Eun Lee

http://www.w3.org/2001/XMLSchema#string

Su Kyung Song

http://www.w3.org/2001/XMLSchema#string

Yeonhee Park

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.

Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial.

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.

An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea.

Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron

Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

P2888

s00520-016-3146-x

P304

3379-3389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-016-3146-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sun Young Rha

Jiyeon Lee

P577

2016-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26984242

http://www.w3.org/2001/XMLSchema#string

Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

about

P2860

P2860

Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698